| Date:                   | 2022.01.26                |  |
|-------------------------|---------------------------|--|
| Your Name:              | Shunfu Zhuang             |  |
| <b>Manuscript Title</b> | :Efficacy analysis of the | ung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ui       | nit —— A retrospective    | <u>study</u>   |
| Manuscript num          | ber (if known):           |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   |   |
|   | manuscript (e.g., funding, provision of study materials, | the Fujian Natural Science<br>Fund (No.2020J011305)  | Temporarily unpaid  |
|   | medical writing, article processing charges, etc.)       |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | _ √ _None  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | _√_None  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | _√_None  |   |

|    | _  |           |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations,                     |           |  |
|    | speakers bureaus,                            |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           | / •       |  |
| 6  | Payment for expert testimony                 | _√_None   |  |
|    | testimony                                    |           |  |
| 7  | Compant for attending                        | / 1       |  |
| /  | Support for attending meetings and/or travel | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _√_None   |  |
|    | pending                                      |           |  |
|    |  |           |  |
| 9  | Participation on a Data                      | √_None    |  |
|    | Safety Monitoring Board or                   |           |  |
|    | Advisory Board                               |           |  |
| 10 | Leadership or fiduciary role                 | _ √ _None |  |
|    | in other board, society,                     |           |  |
|    | committee or advocacy group, paid or unpaid  |           |  |
| 11 | Stock or stock options                       | √ None    |  |
| 11 | Stock of Stock options                       | _ ^ _None |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other                      |           |  |
|    | services                                     |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |
|    |  |           |  |

|   | This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|---|
|   |   |
|   |   |
| l |   |

Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | 2022.01.26                |   |
|-------------------------|---------------------------|---|
| Your Name:              | Hong Wu                   |   |
| <b>Manuscript Title</b> | :Efficacy analysis of the | e lung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ui       | nit —— A retrospectiv     | <u>e study</u>  |
| Manuscript num          | ber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | Time frame: Since the initial None the Fujian Natural Science Fund (No.2020J011305)          | Temporarily unpaid  |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | √_None   |   |
| 3 | Royalties or licenses   | _ √ _None  |   |
| 4 | Consulting fees   | _√_None  |   |

| _  |  | ,         |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations, speakers bureaus,   |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           |           |  |
| 6  | Payment for expert                           | √ None    |  |
| Ĭ  | testimony                                    | _ ' _'''  |  |
|    | •  |           |  |
| 7  | Support for attending meetings and/or travel | _√_None   |  |
|    | G ,  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _ √ _None |  |
|    | pending                                      |           |  |
| •  | 5  | / **      |  |
| 9  | Participation on a Data                      | _√_None   |  |
|    | Safety Monitoring Board or<br>Advisory Board |           |  |
| 10 | Leadership or fiduciary role                 | √ None    |  |
| 10 | in other board, society,                     |           |  |
|    | committee or advocacy                        |           |  |
|    | group, paid or unpaid                        |           |  |
| 11 | Stock or stock options                       | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other services             |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |

| This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|
|   |
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | 2022.01.26                | =   |
|-------------------------|---------------------------|---|
| Your Name:              | Hong Lin                  |   |
| <b>Manuscript Title</b> | :Efficacy analysis of the | lung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ui       | nit —— A retrospective    | <u>study</u>  |
| Manuscript num          | ber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   |   |
|   | manuscript (e.g., funding, provision of study materials, | the Fujian Natural Science<br>Fund (No.2020J011305)  | Temporarily unpaid  |
|   | medical writing, article processing charges, etc.)       |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | _ √ _None  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | _√_None  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | _√_None  |   |

| _  |  | ,         |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations, speakers bureaus,   |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           |           |  |
| 6  | Payment for expert                           | √ None    |  |
| Ĭ  | testimony                                    | _ ' _'''  |  |
|    | •  |           |  |
| 7  | Support for attending meetings and/or travel | _√_None   |  |
|    | G ,  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _ √ _None |  |
|    | pending                                      |           |  |
| •  | 5  | / **      |  |
| 9  | Participation on a Data                      | _√_None   |  |
|    | Safety Monitoring Board or<br>Advisory Board |           |  |
| 10 | Leadership or fiduciary role                 | √ None    |  |
| 10 | in other board, society,                     |           |  |
|    | committee or advocacy                        |           |  |
|    | group, paid or unpaid                        |           |  |
| 11 | Stock or stock options                       | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other services             |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |

| This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|
|   |
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | <u>2022.01.26</u>         | <del></del>   |
|-------------------------|---------------------------|---|
| Your Name:              | Ning Yan                  |   |
| <b>Manuscript Title</b> | :Efficacy analysis of the | lung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ur       | nit —— A retrospective    | <u>study</u>  |
| Manuscript num          | ber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   |   |
|   | manuscript (e.g., funding, provision of study materials, | the Fujian Natural Science<br>Fund (No.2020J011305)  | Temporarily unpaid  |
|   | medical writing, article processing charges, etc.)       |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | _ √ _None  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | _√_None  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | _√_None  |   |

| _  |  | ,         |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations, speakers bureaus,   |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           |           |  |
| 6  | Payment for expert                           | √ None    |  |
| Ĭ  | testimony                                    | _ ' _'''  |  |
|    | •  |           |  |
| 7  | Support for attending meetings and/or travel | _√_None   |  |
|    | G ,  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _ √ _None |  |
|    | pending                                      |           |  |
| •  | 5  | / **      |  |
| 9  | Participation on a Data                      | _√_None   |  |
|    | Safety Monitoring Board or<br>Advisory Board |           |  |
| 10 | Leadership or fiduciary role                 | √ None    |  |
| 10 | in other board, society,                     |           |  |
|    | committee or advocacy                        |           |  |
|    | group, paid or unpaid                        |           |  |
| 11 | Stock or stock options                       | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other services             |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |

| This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|
|   |
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | 2022.01.26                | <del></del>   |
|-------------------------|---------------------------|---|
| Your Name:              | Feifei Zhang              |   |
| <b>Manuscript Title</b> | :Efficacy analysis of the | lung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ui       | nit —— A retrospective    | <u>study</u>  |
| Manuscript num          | ber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   |   |
|   | manuscript (e.g., funding, provision of study materials, | the Fujian Natural Science<br>Fund (No.2020J011305)  | Temporarily unpaid  |
|   | medical writing, article processing charges, etc.)       |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | _ √ _None  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | _√_None  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | _√_None  |   |

| _  |  | ,         |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations, speakers bureaus,   |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           |           |  |
| 6  | Payment for expert                           | √ None    |  |
| Ĭ  | testimony                                    | _ ' _'''  |  |
|    | •  |           |  |
| 7  | Support for attending meetings and/or travel | _√_None   |  |
|    | G ,  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _ √ _None |  |
|    | pending                                      |           |  |
| •  | 5  | / **      |  |
| 9  | Participation on a Data                      | _√_None   |  |
|    | Safety Monitoring Board or<br>Advisory Board |           |  |
| 10 | Leadership or fiduciary role                 | √ None    |  |
| 10 | in other board, society,                     |           |  |
|    | committee or advocacy                        |           |  |
|    | group, paid or unpaid                        |           |  |
| 11 | Stock or stock options                       | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other services             |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |

| This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|
|   |
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | <u>2022.01.26</u>          | =   |
|-------------------------|----------------------------|---|
| Your Name:              | Weiwei Wang                |   |
| <b>Manuscript Title</b> | e:Efficacy analysis of the | lung recruitment maneuver in correcting pulmonary atelectasis in neurological |
| intensive care ui       | nit —— A retrospective     | <u>study</u>  |
| Manuscript num          | nber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | None   |   |
|   | manuscript (e.g., funding, provision of study materials, | the Fujian Natural Science<br>Fund (No.2020J011305)  | Temporarily unpaid  |
|   | medical writing, article processing charges, etc.)       |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | _ √ _None  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | _√_None  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | _√_None  |   |

|    | _  |           |  |
|----|--|-----------|--|
| 5  | Payment or honoraria for                     | _√_None   |  |
|    | lectures, presentations,                     |           |  |
|    | speakers bureaus,                            |           |  |
|    | manuscript writing or                        |           |  |
|    | educational events                           | / •       |  |
| 6  | Payment for expert testimony                 | _√_None   |  |
|    | testimony                                    |           |  |
| 7  | Compant for attending                        | / 1       |  |
| /  | Support for attending meetings and/or travel | _√_None   |  |
|    |  |           |  |
|    |  |           |  |
|    |  |           |  |
| 8  | Patents planned, issued or                   | _√_None   |  |
|    | pending                                      |           |  |
|    |  |           |  |
| 9  | Participation on a Data                      | √_None    |  |
|    | Safety Monitoring Board or                   |           |  |
|    | Advisory Board                               |           |  |
| 10 | Leadership or fiduciary role                 | _ √ _None |  |
|    | in other board, society,                     |           |  |
|    | committee or advocacy group, paid or unpaid  |           |  |
| 11 | Stock or stock options                       | √ None    |  |
| 11 | Stock of Stock options                       | _ ^ _None |  |
|    |  |           |  |
| 12 | Receipt of equipment,                        | _√_None   |  |
|    | materials, drugs, medical                    |           |  |
|    | writing, gifts or other                      |           |  |
|    | services                                     |           |  |
| 13 | Other financial or non-                      | √ _None   |  |
|    | financial interests                          |           |  |
|    |  |           |  |
|    |  |           |  |
|    |  |           |  |

|   | This study was supported by the Fujian Natural Science Fund (NO.2020J011305). |
|---|---|
|   |   |
|   |   |
| l |   |

Please place an "X" next to the following statement to indicate your agreement: